ITM Launches Lumara Bio as Dedicated Oncology Division Ahead of PDUFA Date for Lead Radiopharmaceutical 177Lu-Edotreotide
核心洞察
ITM Isotope Technologies Munich SE (搜索) has introduced Lumara Bio (搜索), a dedicated oncology therapeutics division consolidating its radiopharmaceutical pipeline and development teams.
The lead candidate, 177Lu-edotreotide (ITM-11), is under FDA review with a PDUFA goal date of August 28, 2026, and U.S. commercial readiness activities are already underway.
Lumara Bio (搜索) will advance a diverse pipeline of targeted radiopharmaceutical candidates across multiple cancer types, leveraging ITM's two decades of isotope manufacturing and radiopharmaceutical expertise.
ITM Isotope Technologies Munich SE (搜索), a leading radiopharmaceutical biotech company, today introduced Lumara Bio (搜索) as a dedicated oncology therapeutics division, consolidating its existing pipeline of early- and late-stage radiopharmaceutical therapies under a single, focused organizational structure. The announcement, made from the company's dual headquarters in Garching/Munich, Germany and Princeton, New Jersey, comes as ITM approaches a critical regulatory milestone for its most advanced drug candidate.
Lumara Bio (搜索) will operate as a defined division within ITM, concentrating key resources on commercial readiness for 177Lu-edotreotide (ITM-11), which is currently under review by the U.S. Food and Drug Administration. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 28, 2026, for the new drug application. ITM noted that 177Lu-edotreotide is not yet approved by any regulatory authority for any use.
"As we approach ITM-11's PDUFA date, creating the Lumara Bio (搜索) division enables us to focus our internal efforts and create a structure around the teams responsible for a potential commercial launch," said Dr. Andrew Cavey, chief executive officer of ITM. "In addition, Lumara Bio reflects the evolution of the two pillars of ITM's business and builds on our deep expertise in isotope manufacturing and supply as well as our proven track record in radiopharmaceutical development."
Dr. Cavey further emphasized the division's strategic positioning, stating that "Lumara Bio (搜索) is uniquely positioned to address the growing need for radiopharmaceutical innovation by accelerating progress across our targeted radiopharmaceutical pipeline and expanding our portfolio."
Beyond the lead candidate, Lumara Bio (搜索) will advance ITM's diverse pipeline of targeted radiopharmaceutical candidates spanning multiple cancer types, treatment approaches, and proprietary isotope platforms. The division builds on ITM's scientific foundation and more than two decades of radiopharmaceutical expertise, as well as its established radiopharmaceutical development capabilities and strategic scientific collaborations. Lumara Bio will leverage ITM's isotope manufacturing and supply services to support both its pipeline development and potential commercial launch activities.
ITM's broader precision oncology pipeline includes multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company aims to provide a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors, with improved patient benefit as the driving principle across all activities.
The creation of Lumara Bio (搜索) represents a significant organizational evolution for ITM as it transitions from a pure development-stage company toward potential commercialization, while maintaining its commitment to advancing targeted radiopharmaceutical innovation for cancers where treatment options remain limited.